Group 1 - The core viewpoint of the news is that Hendi Pharmaceutical experienced a decline in stock price and trading volume, with significant changes in financing and stockholder metrics [1][2]. Group 2 - On December 23, Hendi Pharmaceutical's stock fell by 2.35%, with a trading volume of 88.08 million yuan. The financing buy-in amount was 7.56 million yuan, while the financing repayment was 6.23 million yuan, resulting in a net financing buy of 1.33 million yuan [1]. - As of December 23, the total financing and securities lending balance for Hendi Pharmaceutical was 124 million yuan, which is 2.39% of its circulating market value, indicating a low financing balance compared to the past year [1]. - In terms of securities lending, on December 23, Hendi Pharmaceutical repaid 900 shares and sold 900 shares, with a selling amount of 11,200 yuan. The remaining securities lending volume was 22,300 shares, with a balance of 277,400 yuan, which is at a high level compared to the past year [1]. Group 3 - As of December 19, the number of shareholders for Hendi Pharmaceutical was 21,400, a decrease of 3.15%, while the average circulating shares per person increased by 3.25% to 19,531 shares [2]. - For the period from January to September 2025, Hendi Pharmaceutical reported an operating income of 319 million yuan, a year-on-year decrease of 4.52%, and a net profit attributable to shareholders of 20.93 million yuan, down 71.96% year-on-year [2]. - Since its A-share listing, Hendi Pharmaceutical has distributed a total of 378 million yuan in dividends, with 306 million yuan distributed over the past three years [2].
亨迪药业12月23日获融资买入755.87万元，融资余额1.24亿元